Safety study of MF1 for Parkinson's-related constipation
Part of Brain & nervous system clinical trials.
This early-phase study tests a new treatment called MF1 for Parkinson's-related symptoms, especially constipation. It first checks safety in healthy volunteers, then in people with Parkinson's who have slow bowel movements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- If you are a healthy volunteer, you must be a Japanese male between 18 and 44 years old with a BMI between 18.5 and 25.
- If you have Parkinson's disease, you must be between 40 and 84 years old with a diagnosis of idiopathic Parkinson's (stage 3 or lower).
- Your Parkinson's medication must be stable for at least 8 weeks: selegiline (5 mg twice daily), rasagiline (1 mg daily), or carbidopa/levodopa (25/100 mg three times daily).
- You must have chronic constipation (fewer than 2 bowel movements per week or hard stools).
- You cannot have certain medical conditions (like epilepsy, severe allergies, or liver/kidney problems) or be taking blood thinners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new single-dose treatment for Parkinson's disease to see if it can help reduce 'off' time—when medication wears off and symptoms return. It is for people who experience motor fluctuations and are already on a stable medication routine.
This trial tests a new drug called VT-5006 to see if it is safe for people with Parkinson's disease. It focuses on those who have stomach or bowel issues, like constipation.
This trial tests whether pyridostigmine can improve constipation symptoms in people with Parkinson’s disease. If you have Parkinson’s and functional constipation (with infrequent bowel movements), this study may offer a new medication option and closely track your bowel function.
This study tests whether a treatment called fecal microbiota transplantation (FMT) can help relieve constipation in people with Parkinson's disease. FMT uses healthy donor stool to improve gut bacteria, which may ease constipation and possibly improve Parkinson's symptoms.
This study tests whether a medication called tenapanor can help relieve constipation in people with Parkinson's disease. If you have Parkinson's and have been struggling with constipation for at least 6 months, this trial may offer a new option to improve bowel regularity.
This study tests a new oral medication called EC5026 for Parkinson's disease. It aims to see if the drug is safe and if it might help control symptoms when added to your current levodopa treatment.
Hear when a new PARKINSON DISEASE (Disorder) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.